All In Biotech

Drug Trial Radar · NCT03259789

Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Bexagliflozin in Subjects With Type 2 Diabetes Mellitus Who Are Not Adequately Controlled by Metformin Alone

Last checked: Nov 20, 2026Latest source record: Jul 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 351 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

351

Actual

Start

Nov 28, 2017

Primary completion

Jan 23, 2019

Study completion Jan 23, 2019

Sponsor

Lead sponsor
TheracosIndustry
Sponsor type
Industry
First posted
Aug 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the effect of bexagliflozin compared to placebo as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).

Conditions

  • Type2 Diabetes Mellitus

Interventions

  • Bexagliflozin tablets, 20 mgDrug

    Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.

  • Bexagliflozin tablets, placeboDrug

    Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

  • Bexagliflozin tablets, 20 mgDrug

    Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in HbA1c at Week 24 for Double-blind GroupTime frame: Baseline to week 24
  2. Change From Baseline in HbA1c at Week 24 for High Glycemic GroupTime frame: Baseline to week 24

Locations

43 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Research Site 1232

    Birmingham, Alabama

  • Clinical Research Site 1378

    Birmingham, Alabama

  • Clinical Research Site 1269

    Foley, Alabama

  • Clinical Research Site 1363

    Little Rock, Arkansas

  • Clinical Research Site 1381

    Anaheim, California

  • Clinical Research Site 1375

    North Hollywood, California

  • Clinical Research Site 1365

    Norwalk, California

  • Clinical Research Site 1382

    Norwalk, Connecticut

  • Clinical Research Site 1372

    Hollywood, Florida

  • Clinical Research Site 1362

    Palm Springs, Florida

  • Clinical Research Site 1373

    Pembroke Pines, Florida

  • Clinical Research Site 1376

    Nampa, Idaho

  • Clinical Research Site 1366

    Chicago, Illinois

  • Clinical Research Site 1294

    New Orleans, Louisiana

  • Clinical Research Site 1374

    St Louis, Missouri

  • Clinical Research Site 1370

    Las Vegas, Nevada

  • Clinical Research Site 1009

    Berlin, New Jersey

  • Clinical Research Site 1037

    Trenton, New Jersey

  • Clinical Research Site 1286

    Albuquerque, New Mexico

  • Clinical Research Site 1368

    New York, New York

  • Clinical Research Site 1275

    The Bronx, New York

  • Clinical Research Site 1019

    Portland, Oregon

  • Clinical Research Site 1379

    Gonzales, Texas

  • Clinical Research Site 1369

    Houston, Texas

  • Clinical Research Site 1371

    San Antonio, Texas

  • Clinical Research Site 1360

    San Antonio, Texas

  • Clinical Research Site 6040

    Fukuoka, Japan

  • Clinical Research Site 6043

    Kyoto, Japan

  • Clinical Research Site 6015

    Osaka, Japan

  • Clinical Research Site 6045

    Tokyo, Japan

  • Clinical Research Site 6047

    Tokyo, Japan

  • Clinical Research Site 6048

    Nagoya, Aichi-ken, Japan

  • Clinical Research Site 6050

    Sapporo, Hokkaido, Japan

  • Clinical Research Site 6041

    Koga, Ibaraki, Japan

  • Clinical Research Site 6029

    Atsugi, Kanagawa, Japan

  • Clinical Research Site 6051

    Kamakura, Kanagawa, Japan

  • Clinical Research Site 6020

    Yokohama, Kanagawa, Japan

  • Clinical Research Site 6055

    Tokyo, Meguro, Japan

  • Clinical Research Site 6046

    Higashiosaka, Osaka, Japan

  • Clinical Research Site 6033

    Kashihara, Osaka, Japan

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.